NewAmsterdam's Amgen castoff cuts LDL cholesterol in phase 2, opening new front in race to market

NewAmsterdam Pharma has advanced its bid to write a new chapter in the story of an Amgen castoff by linking the CETP inhibitor to reductions in LDL cholesterol when used as an adjunct to high-intensity statin therapy. The Dutch biotech plans to start a phase 3 trial on the strength of the data.